Compare SELX & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SELX | NNVC |
|---|---|---|
| Founded | 2021 | 2005 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.0M | 24.4M |
| IPO Year | N/A | N/A |
| Metric | SELX | NNVC |
|---|---|---|
| Price | $0.76 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 201.2K | ★ 290.5K |
| Earning Date | 05-08-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,974,593.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 243.84 | N/A |
| 52 Week Low | $0.52 | $0.94 |
| 52 Week High | $1.85 | $2.23 |
| Indicator | SELX | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 39.32 |
| Support Level | $0.71 | $1.13 |
| Resistance Level | $0.80 | $1.16 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 22.24 | 7.32 |
Semilux International Ltd is a company that operates through its subsidiaries which is an optical and 3D sensing technology company that is involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR).
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.